Two stocks in Drug Manufacturers - General
AbbVie vs Bristol-Myers Squibb: profit, growth, debt and price compared
Bristol-Myers Squibb is stronger on 3 of 6 figures: profit margin, price for its expected profit and dividend. AbbVie is stronger on 2: sales growth and price trend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AbbVieABBV | Bristol-Myers SquibbBMY | |
|---|---|---|
| Net margin | 15.7% | Stronger: 18.5% |
| Revenue growth, past year | Stronger: +10.32% | +6.93% |
| Debt to equity | — | 191.5% |
| Forward P/E | 17.6× | Stronger: 8.9× |
| Dividend yield | 2.42% | Stronger: 4.23% |
| Analysts | Buy · 26 | Buy · 24 |
| From its 200-day average | Stronger: +15.5% | +1.2% |
Share price over the past year
- AbbVie+22.3%
- Bristol-Myers Squibb+26.6%
18 Nov 202518 Nov 2026
AbbVie or Bristol-Myers Squibb: which is stronger?
- BMY
Which is more profitable?
Bristol-Myers Squibb keeps more of each sale as profit: 18.5% against 15.7%.
- ABBV
Which is growing its sales faster?
AbbVie is growing its sales faster: +10.32% over the past year, against +6.93%.
- BMY
Which costs less for the profit it is expected to make?
Bristol-Myers Squibb costs less for the profit it is expected to make: 8.9× its forward earnings, against 17.6×.
- BMY
Which pays more in dividends?
Bristol-Myers Squibb pays more back in dividends for what a share costs: 4.23% a year, against 2.42%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- ABBV
Which is in the stronger price trend?
AbbVie's price is in the stronger trend: 15.5% above its 200-day average, against 1.2% above.
What each company does
ABBVAbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Reports results on 3 February 2027
BMYBristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Reports results on 4 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.